Lacrimal drainage obstruction in gastric cancer patients receiving s-1 chemotherapy

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2065-2071

  Kim, N ^a   Park, C ^b   Park, D J ^a   Kim, H H ^a   Kim, S ^a,b   Kim, Y J ^a   Kim, J H ^a   Lee, J S ^a   Bang, Y J ^b   Khwarg, S I ^b   Choung, H ^c   Lee, M J ^d   Lee, K W ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Hallym University   (South Korea)

Author keywords

Chemotherapy; Gastric cancer; Lacrimal drainage obstruction; S 1

Indexed keywords

CREATININE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CREATININE CLEARANCE; EPIPHORA; FEMALE; HUMAN; LACRIMAL DUCT; LACRIMAL DUCT OCCLUSION; MAJOR CLINICAL STUDY; MALE; PARTIAL GASTRECTOMY; PRIORITY JOURNAL; RISK FACTOR; STOMACH CANCER; TOTAL STOMACH RESECTION;

EID: 84864910462     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds106     Document Type: Article

References (34)

1. Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
2. Sasako M, Kinoshita T, Furukawa H et al. Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy (ACTS-GC study). Ann Oncol 2010; 21 (Suppl 8): viii225 (Abstr 709PD).
3. Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
4. Choi IS, Lee KW, Kim KH et al. Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer. Med Oncol 2010; 27: 992-997.
5. Boku N, Yamamoto S, Fukuda H et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
6. Ajani JA, Rodriguez W, Bodoky G et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28: 1547-1553.
7. Kim YH. Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat 2005; 37: 79-86.
8. Muro K, Boku N, Shimada Y et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 2010; 11: 853-860.
9. Okamoto I, Yoshioka H, Morita S et al. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 2010; 28: 5240-5246.
10. Kim YJ, Im SA, Kim HG et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol 2008; 19: 99-103.
11. Esmaeli B, Valero V, Ahmadi MA et al. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001; 108: 994-995.
12. Esmaeli B, Ahmadi MA, Rivera E et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180-1182.
13. Esmaeli B, Hortobagyi GN, Esteva FJ et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109: 1188-1191.
14. Esmaeli B, Amin S, Valero V et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006; 24: 3619-3622.
15. Leyssens B, Wildiers H, Lobelle JP et al. A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxelinduced dacryostenosis. Ann Oncol 2010; 21: 419-423.
16. Kintzel PE, Michaud LB, Lange MK. Docetaxel-associated epiphora. Pharmacotherapy 2006; 26: 853-867.
17. Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand 2000; 78: 110-113.
18. Eiseman AS, Flanagan JC, Brooks AB et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg 2003; 19: 216-224.
19. Esmaeli B, Golio D, Lubecki L et al. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol 2005; 140: 325-327.
20. Park J-S, Ha SW, Lew H. Two cases of lacrimal drainage obstruction associated with S-1 anticancer treatment. J Korean Ophthalmol Soc 2010; 51: 890-894.
21. Kitamura H, Miyanaga T, Shin H et al. Investigation of epiphora following S-1 therapy. Gan To Kagaku Ryoho 2011; 38: 259-262.
22. Lee KW, Bang SM, Kim S et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost 2010; 8: 540-547.
23. Kim KH, Lee KW, Baek SK et al. Survival benefit of gastrectomy +/- metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer 2011; 14: 130-138.
24. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer 1998; 1: 10-24.
25. Iwasa S, Yamada Y, Fukagawa T et al. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 2011; 14: 28-34.
26. McCartney E, Valluri S, Rushing D et al. Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthal Plast Reconstr Surg 2007; 23: 170-171.
27. Hassan A, Hurwitz JJ, Burkes RL. Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol 1998; 33: 14-19.
28. Christophidis N, Vajda FJ, Lucas I et al. Ocular side effects with 5-fluorouracil. Aust N Z J Med 1979; 9: 143-144.
29. Loprinzi CL, Love RR, Garrity JA et al. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. Cancer Invest 1990; 8: 459-465.
30. Yamanaka T, Matsumoto S, Teramukai S et al. Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer 2007; 10: 129-134.
31. Fujita K, Yamamoto W, Endo S et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 2008; 99: 1049-1054.
32. Kim WY, Nakata B, Hirakawa K. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy. Cancer Sci 2007; 98: 1604-1608.
33. Tsuruoka Y, Kamano T, Kitajima M et al. Effect of gastrectomy on the pharmacokinetics of 5-fluorouracil and gimeracil after oral administration of S-1. Anticancer Drugs 2006; 17: 393-399.
34. Kochi M, Fujii M, Kanamori N et al. Effect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patients. Cancer Chemother Pharmacol 2007; 60: 693-701.